Document is current
Any future updates will be listed below
-
Authors
Polhemus, Ashley http://orcid.org/0000-0002-5056-5785
Ortiz, Laura Delgado http://orcid.org/0000-0003-0311-7661
Brittain, Gavin http://orcid.org/0000-0002-9903-7203
Chynkiamis, Nikolaos http://orcid.org/0000-0002-9595-6974
Salis, Francesca
Gaßner, Heiko http://orcid.org/0000-0003-2037-9460
Gross, Michaela
Kirk, Cameron
Rossanigo, Rachele
Taraldsen, Kristin
Balta, Diletta
Breuls, Sofie http://orcid.org/0000-0002-6474-6923
Buttery, Sara
Cardenas, Gabriela
Endress, Christoph
Gugenhan, Julia
Keogh, Alison
Kluge, Felix http://orcid.org/0000-0003-4921-6104
Koch, Sarah
Micó-Amigo, M. Encarna
Nerz, Corinna http://orcid.org/0000-0001-5160-796X
Sieber, Chloé http://orcid.org/0000-0002-6642-5082
Williams, Parris
Bergquist, Ronny
de Basea, Magda Bosch
Buckley, Ellen http://orcid.org/0000-0002-0968-6286
Hansen, Clint http://orcid.org/0000-0003-4813-3868
Mikolaizak, A. Stefanie
Schwickert, Lars
Scott, Kirsty
Stallforth, Sabine
van Uem, Janet
Vereijken, Beatrix http://orcid.org/0000-0002-2231-8138
Cereatti, Andrea
Demeyer, Heleen
Hopkinson, Nicholas http://orcid.org/0000-0003-3235-0454
Maetzler, Walter http://orcid.org/0000-0002-5945-4694
Troosters, Thierry
Vogiatzis, Ioannis
Yarnall, Alison
Becker, Clemens
Garcia-Aymerich, Judith http://orcid.org/0000-0002-7097-4586
Leocani, Letizia
Mazzà, Claudia
Rochester, Lynn
Sharrack, Basil
Frei, Anja
Puhan, Milo
,
-
License Information
Text and Data Mining valid from 2021-10-14
Version of Record valid from 2021-10-14
-
More Information
Article History
Received: 10 May 2021
Accepted: 9 August 2021
First Online: 14 October 2021
Competing interests
: The authors declare the following competing interests: W.M. receives or received funding from the European Union, the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Rölke Pharma. and UCB, was invited to Advisory Boards of Abbvie, Biogen, Lundbeck. and Market Access & Pricing Strategy GmbH, and is an advisory board member of the Critical Path for Parkinson’s Consortium. He serves as the cochair of the MDS Technology Task Force. The remaining authors declare no competing interests.
